The report will be delivered in 2-3 business days.

Drugs For Benign Prostatic hypertrophy Global Market Report 2020-30: Covid 19 Impact and Recovery

Starting Price : $ 4000.00 | Pages : 200 | Published : September 2020 | SKU CODE : 7222 | Format :


The drugs for benign prostatic hypertrophy market consists of sales of benign prostatic hypertrophy drugs to treat enlarged prostate glands. Benign Prostatic Hypertrophy is commonly seen in men older than age 50.

The global drugs for benign prostatic hypertrophy market is expected to decline from $4.6 billion in 2019 to $3.7 billion in 2020 at a compound annual growth rate (CAGR) of -18.7%. The decline is mainly due to the disruption caused by the lockdown measure across various countries to contain COVID-19 spread. Currently there is less demand for genito-urinary drugs mainly as people are staying at home and are less likely to get exposed to factors that might cause genito-urinary infections, or other hormonal diseases caused by lifestyle changes or eating habits. The market is then expected to recover and grow at a CAGR of 6.2% from 2021 and reach $5.8 billion in 2023.

North America was the largest region in the drugs for benign prostatic hypertrophy market in 2018, followed by Europe and Asia Pacific. This region is expected to remain the largest during the next five years. The drugs for benign prostatic hypertrophy market in Asia Pacific is forecasted to register the highest CAGR during 2018-2023.

The rising male geriatric population globally is driving the market for Benign Prostatic Hypertrophy drugs as the condition is commonly seen in men aged over 50 years. According to the United Nations 2017 World Population Ageing Report, the number of people aged 60 years or above was 962 million in 2017 and is expected to double to around 2.1 billion by 2050. According to the National Institute of Health( NIH),  Benign Prostatic Hyperplasia affects around 50% of men aged between 51 and 60 years and up to 90% of men aged over 80 years. 

Increasing adoption of minimally invasive surgeries due to advancements in technology is restraining the growth of Benign Prostatic Hyperplasia drugs market. Minimally invasive surgeries cause less pain and are generally conducted on an outpatient basis. This eliminates the need to consume Benign Prostatic Hyperplasia drugs, acting as a restraint on the market. Some of the minimally invasive surgeries used to treat Benign Prostatic Hyperplasia include laparoscopic prostatectomy, transurethral microwave thermotherapy (TUMT) and transurethral needle ablation (TUNA).

Combination drugs are increasingly being used in the treatment of Benign Prostatic Hypertrophy as they are more effective and help prevent disease progression. A combination drug includes two or more active pharmaceutical ingredients (APIs) combined in a single dosage form. These drugs reduce the development of drug resistance, have fewer side effects and low treatment failure rate. For instance, Duodart, a combination of dutasteride and tamsulosin hydrochloride is increasingly being prescribed for the treatment of Benign Prostatic Hypertrophy.

Benign prostatic hypertrophy drugs manufacturers globally are regulated by various regulatory bodies. For instance, in the European Union, the EU legislation authorizes medicines based on quality, safety, and efficacy. Companies are mandated to submit compliance documentation for suitable quality before applying for authorization. Manufacturers are required to demonstrate safety and efficacy of drugs using clinical trials data which will be assessed by competent authorities before authorizing for sale.

The major players covered in the global drugs for benign prostatic hypertrophy market are Allergan PLC,  Astellas Pharma Inc.,  Boehringer Ingelheim,  Eli Lilly and Company,  GlaxoSmithKline PLC, Teva Pharmaceutical Industries Limited,  Sanofi,  Nymox Pharmaceutical Corporation, AEternaZentaris Inc.,  Pfizer Inc., GlaxoSmithKline,  IntelGenx Technologies Corp.,  Ipsen S.A.,  Novartis AG,  Protox Therapeutics Inc. ,  Valeant Pharmaceuticals Inc.,  Bayer AG,  Quest PharmaTech Inc.,  Bristol-Myers Squibb and Company, Indevus Pharmaceuticals Inc., Kaken Pharmaceutical Co., LTD., Impax Laboratories, Inc., GemVax & KAEL Co. Ltd.,  Merck & Co. Inc., Kissei Pharmaceuticals Co., Ltd..

The countries covered in the global drugs for benign prostatic hypertrophy market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia.

The regions covered in the global drugs for benign prostatic hypertrophy market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The global drugs for benign prostatic hypertrophy market is segmented - 1) By Type: Alpha Blocker, 5-alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, Others. 2) By End User: Hospital Pharmacies, Retail Pharmacies, Others.

    1. Executive Summary

    2. Drugs for Benign Prostatic Hypertrophy Market Characteristics

    3. Drugs for Benign Prostatic Hypertrophy Market Size And Growth

    3.1. Global Drugs for Benign Prostatic Hypertrophy Historic Market, 2015-2019, $ Billion

    3.1.1. Drivers Of The Market

    3.1.2. Restraints On The Market

    3.2. Global Drugs for Benign Prostatic Hypertrophy Forecast Market, 2019-2023F, 2025F, 2030F, $ Billion

    3.2.1. Drivers Of The Market

    3.2.2. Restraints On the Market

    4. Drugs for Benign Prostatic Hypertrophy Market Segmentation

    4.1. Global Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    Alpha Blocker

    5-alpha Reductase Inhibitor

    Phosphodiesterase-5 Inhibitor

    Others

    4.2. Global Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    Hospital Pharmacies

    Retail Pharmacies

    Online Pharmacies

    5. Drugs for Benign Prostatic Hypertrophy Market Regional And Country Analysis

    5.1. Global Drugs for Benign Prostatic Hypertrophy Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    5.2. Global Drugs for Benign Prostatic Hypertrophy Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    6. Asia-Pacific Drugs for Benign Prostatic Hypertrophy Market  

    6.1. Asia-Pacific Drugs for Benign Prostatic Hypertrophy Market Overview  

    6.2. Asia-Pacific Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    6.3. Asia-Pacific Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    7. China Drugs for Benign Prostatic Hypertrophy Market  

    7.1. China Drugs for Benign Prostatic Hypertrophy Market Overview  

    7.2. China Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion

    7.3. China Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion

    8. India Drugs for Benign Prostatic Hypertrophy Market  

    8.1. India Drugs for Benign Prostatic Hypertrophy Market Overview  

    8.2. India Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    8.3. India Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    9. Japan Drugs for Benign Prostatic Hypertrophy Market  

    9.1. Japan Drugs for Benign Prostatic Hypertrophy Market Overview  

    9.2. Japan Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    9.3. Japan Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    10. Australia Drugs for Benign Prostatic Hypertrophy Market  

    10.1. Australia Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    10.2. Australia Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    11. Indonesia Drugs for Benign Prostatic Hypertrophy Market  

    11.1. Indonesia Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    11.2. Indonesia Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    12. South Korea Drugs for Benign Prostatic Hypertrophy Market  

    12.1. South Korea Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    12.2. South Korea Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    13. Western Europe Drugs for Benign Prostatic Hypertrophy Market  

    13.1. Western Europe Drugs for Benign Prostatic Hypertrophy Market Overview

    13.2. Western Europe Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    13.3. Western Europe Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    14. UK Drugs for Benign Prostatic Hypertrophy Market  

    14.1. UK Drugs for Benign Prostatic Hypertrophy Market Overview

    14.2. UK Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    14.3. UK Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    15. Germany Drugs for Benign Prostatic Hypertrophy Market  

    15.1. Germany Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    15.2. Germany Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    16. France Drugs for Benign Prostatic Hypertrophy Market  

    16.4. France Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    16.5. France Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    17. Eastern Europe Drugs for Benign Prostatic Hypertrophy Market  

    17.1. Eastern Europe Drugs for Benign Prostatic Hypertrophy Market Overview

    17.2. Eastern Europe Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    17.3. Eastern Europe Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    18. Russia Drugs for Benign Prostatic Hypertrophy Market  

    18.1. Russia Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    18.2. Russia Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    19. North America Drugs for Benign Prostatic Hypertrophy Market  

    19.1. North America Drugs for Benign Prostatic Hypertrophy Market Overview

    19.2. North America Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    19.3. North America Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    20. USA Drugs for Benign Prostatic Hypertrophy Market  

    20.1. USA Drugs for Benign Prostatic Hypertrophy Market Overview

    20.2. USA Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    20.3. USA Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    21. South America Drugs for Benign Prostatic Hypertrophy Market  

    21.1. South America Drugs for Benign Prostatic Hypertrophy Market Overview

    21.2. South America Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    21.3. South America Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    22. Brazil Drugs for Benign Prostatic Hypertrophy Market  

    22.1. Brazil Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    22.2. Brazil Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    23. Middle East Drugs for Benign Prostatic Hypertrophy Market  

    23.1. Middle East Drugs for Benign Prostatic Hypertrophy Market Overview

    23.2. Middle East Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    23.3. Middle East Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    24. Africa Drugs for Benign Prostatic Hypertrophy Market  

    24.1. Africa Drugs for Benign Prostatic Hypertrophy Market Overview

    24.2. Africa Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    24.3. Africa Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    25. Drugs for Benign Prostatic Hypertrophy Market Competitive Landscape And Company Profiles

    25.1. Drugs for Benign Prostatic Hypertrophy Market Competitive Landscape

    25.2. Drugs for Benign Prostatic Hypertrophy Market Company Profiles

    25.2.1. Allergan PLC

    25.2.1.1. Overview

    25.2.1.2. Products and Services

    25.2.1.3. Strategy

    25.2.1.4. Financial Performance

    25.2.2.  Astellas Pharma Inc.

    25.2.2.1. Overview

    25.2.2.2. Products and Services

    25.2.2.3. Strategy

    25.2.2.4. Financial Performance

    25.2.3.  Boehringer Ingelheim

    25.2.3.1. Overview

    25.2.3.2. Products and Services

    25.2.3.3. Strategy

    25.2.3.4. Financial Performance

    25.2.4.  Eli Lilly and Company

    25.2.4.1. Overview

    25.2.4.2. Products and Services

    25.2.4.3. Strategy

    25.2.4.4. Financial Performance

    25.2.5.  GlaxoSmithKline PLC

    25.2.5.1. Overview

    25.2.5.2. Products and Services

    25.2.5.3. Strategy

    25.2.5.4. Financial Performance

    26. Key Mergers And Acquisitions In The Drugs for Benign Prostatic Hypertrophy Market

    27. Drugs for Benign Prostatic Hypertrophy Market Trends And Strategies

    28. Product Pipeline Analysis

    29. Drugs for Benign Prostatic Hypertrophy Market Future Outlook and Potential Analysis

    30. Appendix

    30.1. Abbreviations

    30.2. Currencies

    30.3. Research Inquiries

    30.4. The Business Research Company

    30.5. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2015-2019, $ Billion
  • Table 2: Global Forecast Market Growth, 2019-2023F, 2025F, 2030F, $ Billion
  • Table 3: Global Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 4: Global Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 5: Global Drugs for Benign Prostatic Hypertrophy Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 6: Global Drugs for Benign Prostatic Hypertrophy Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 7: Asia-Pacific, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 8: Asia-Pacific, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 9: China, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 10: China, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 11: India, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 12: India, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 13: Japan, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 14: Japan, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 15: Australia, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 16: Australia, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 17: Indonesia, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 18: Indonesia, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 19: South Korea, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 20: South Korea, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 21: Western Europe, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 22: Western Europe, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 23: UK, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 24: UK, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 25: Germany, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 26: Germany, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 27: France, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 28: France, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 29: Eastern Europe, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 30: Eastern Europe, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 31: Russia, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 32: Russia, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 33: North America, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 34: North America, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 35: USA, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 36: USA, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 37: South America, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 38: South America, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 39: Brazil, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 40: Brazil, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 41: Middle East, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 42: Middle East, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 43: Africa, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 44: Africa, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 45: Allergan PLC Financial Performance
  • Table 46: Astellas Pharma Inc. Financial Performance
  • Table 47: Boehringer Ingelheim Financial Performance
  • Table 48: Eli Lilly and Company Financial Performance
  • Table 49: GlaxoSmithKline PLC Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2015-2019, $ Billion
  • Figure 2: Global Forecast Market Growth, 2019-2023F, 2025F, 2030F, $ Billion
  • Figure 3: Global Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 4: Global Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 5: Global Drugs for Benign Prostatic Hypertrophy Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 6: Global Drugs for Benign Prostatic Hypertrophy Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 7: Asia-Pacific, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 8: Asia-Pacific, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 9: China, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 10: China, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 11: India, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 12: India, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 13: Japan, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 14: Japan, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 15: Australia, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 16: Australia, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 17: Indonesia, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 18: Indonesia, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 19: South Korea, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 20: South Korea, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 21: Western Europe, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 22: Western Europe, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 23: UK, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 24: UK, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 25: Germany, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 26: Germany, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 27: France, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 28: France, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 29: Eastern Europe, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 30: Eastern Europe, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 31: Russia, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 32: Russia, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 33: North America, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 34: North America, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 35: USA, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 36: USA, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 37: South America, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 38: South America, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 39: Brazil, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 40: Brazil, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 41: Middle East, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 42: Middle East, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 43: Africa, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 44: Africa, Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 45: Allergan PLC Financial Performance
  • Figure 46:  Astellas Pharma Inc. Financial Performance
  • Figure 47:  Boehringer Ingelheim Financial Performance
  • Figure 48:  Eli Lilly and Company Financial Performance
  • Figure 49:  GlaxoSmithKline PLC Financial Performance
New Drug Innovations In The Pharmaceuticals Market
Antithrombotic Drugs Are Being Used To Prevent Various Disorders
Increasing Rate Of The Elder Population Is Driving The Ophthalmology Drugs Market
Innovations In The Diabetes Therapies Market
Allergan plc- One Of The Largest Companies In The Global Drugs For Benign Prostatic Hypertrophy Market
Innovation And Development Of Combination Drugs To Enhance Growth Of The Ovarian Cancer Drugs Market
The Global Prostate Cancer Drugs Market Will Reach Around $10 By 2022
Antivirals Are The Largest And Fastest Growing Segment Of The Anti-Infective Drugs Market
Ophthalmology Drugs Market - By Type (Antglaucoma Drugs, Dry Eye Medication And Other Ophthalmological Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores And Others), By Drug Classification (Branded Drugs And Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) And, By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Dry Eye Medication Market - By Type (Aqueous Dry Eye Syndrome, Evaporative Dry Eye Syndrome), By End-User (Hospital Pharmacies, Eye Health Clinics, Retail Pharmacies, Online Pharmacies), By Product Type (Liquid Drops, Gel, Liquid Wipes, Eye Ointment), And By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Coronavirus (COVID-19) Current Therapy Market Global Report 2020: COVID 19 Growth And Change
View Report
COVID19 Drug Associated APIs Market Global Report 2020: COVID 19 Growth And Change
View Report
COVID19 Vaccine & Therapeutics Clinical Trial Analysis 2020
View Report
COVID19 Vaccine And Therapeutics Pipeline Analysis 2020
View Report
Remdesivir Market Global Report 2020-30: COVID 19 Growth and Change
View Report
Biologics Market - By Types (Monoclonal Antibodies, Therapeutic Proteins And Vaccines), Trends, By Key Market Players, And By Region, Opportunities And Strategies – Global Forecast To 2021
View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)